Metabiomics
  • Home
  • LifeKit® Prevent
  • Technology
    • Microbiome Health
    • Microbiome Research News
    • Publications
  • About Us
    • Press Releases
    • Management
    • Careers
  • Contact Us
Select Page
Prescient Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening

Prescient Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening

by Greg Kuehn | Mar 20, 2020 | Research News

Research will examine prevalent gut microbial markers present in colorectal cancer CARLSBAD, Calif., June 2, 2020 /PRNewswire/ — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., announced today a research...
Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test

Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test

by Greg Kuehn | Dec 17, 2019 | Research News

CARLSBAD, Calif., Dec. 17, 2019 /PRNewswire/ — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of OraSure Technologies, Inc., announced today a collaboration to develop a new test called LifeKit®...
Abstract: Use of the Microbiome as a Biomarker to Identify Patients with Colorectal Polyps

Abstract: Use of the Microbiome as a Biomarker to Identify Patients with Colorectal Polyps

by Greg Kuehn | Apr 15, 2018 | Research News

Patrick M. Gillevet, Ezzat Dadkhah, Masoumeh Sikaroodi, Swati Dalmet, Louis Y. Korman, Robert Hardi, Jeffrey H. Baybick, David K. Hanzel, Greg Kuehn, Thomas Kuehn Background: Alterations in the colonic microbiota are likely to play a role in colonic...
Metabiomics Concludes Colorectal Polyp Study with 232 Subjects Enrolled

Metabiomics Concludes Colorectal Polyp Study with 232 Subjects Enrolled

by Greg Kuehn | Jun 19, 2017 | Press Releases, Research News

Manassas, VA, June 19, 2017 – Metabiomics is proud to announce the completion of one of the largest case-controlled studies on the colorectal polyp microbiome.  Titled “Metabiomics Neoplasia Clinical Research Study”, also referred to as MB-01 by Metabiomics, the...
Metabiomics Launches IRB approved Colon Polyp and Colon Cancer Diagnostics Clinical Research Study

Metabiomics Launches IRB approved Colon Polyp and Colon Cancer Diagnostics Clinical Research Study

by Greg Kuehn | Mar 17, 2014 | Research News

Chevy Chase, MD, March 17, 2014 Metabiomics is pleased to announce the launch of a new IRB approved microbiome clinical research study titled “Metabiomics Neoplasia Clinical Research Study”, also referred to as MB-01.   The ~200 patient study will be conducted in...
MultiTag™ Sequencing Patent Award in US Clears Path for Metabiomics Colorectal Cancer and Gastrointestinal Disease Molecular Diagnostic Clinical Trials

MultiTag™ Sequencing Patent Award in US Clears Path for Metabiomics Colorectal Cancer and Gastrointestinal Disease Molecular Diagnostic Clinical Trials

by Greg Kuehn | Dec 10, 2013 | Research News

POTOMAC FALLS, VA, December 10, 2013 Metabiomics is pioneering the development of molecular diagnostic tests for colorectal cancer, inflammatory bowel disease, and other gastrointestinal cancers and autoimmune diseases built on an exclusive worldwide license from...
« Older Entries

Recent News

  • Prescient Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening March 20, 2020
  • Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test December 17, 2019
  • FDA Grants Breakthrough Designation to the Prescient Metabiomics LifeKit® Prevent Test for the Early Detection of Colon Polyps and Colon Cancer September 5, 2019

Tag Cloud

Breakthrough Device China clinical studies colon cancer screening colon cancer test colon polyp Colorado Capital Conference colorectal adenoma colorectal cancer colorectal cancer diagnostics colorectal cancer screening CoreBiome Curtis Huttenhower Dan Knights Harvard Investor conference Keri Donaldson Kindstar LifeKit Prevent MB-01 MBAC Metabiomics Metagenomics Microbiome microbiome diagnostics microbiome sampling kit Mid-Atlantic Bio molecular diagnostics MultiTag Sequencing neoplasia Next-Generation Sequencing OCTANe Medical Device & Investor Forum Oricol Origin Sciences patents Patrick Gillevet Prescient Medicine Series A

RSS Feeds

  • RSS - Posts
  • RSS - Comments

Recent News

  • Prescient Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening
  • Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test
  • FDA Grants Breakthrough Designation to the Prescient Metabiomics LifeKit® Prevent Test for the Early Detection of Colon Polyps and Colon Cancer

Navigation

  • Home
  • LifeKit® Prevent
  • Technology
    • Microbiome Health
    • Microbiome Research News
    • Publications
  • About Us
    • Press Releases
    • Management
    • Careers
  • Contact Us
  • Facebook
  • X
  • RSS

Designed by Elegant Themes | Powered by WordPress

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}